Every few years, drug development goes through a moment where a new technology promises to change everything. Artificial ...
The FDA has started a priority review of AstraZeneca's IL-33-targeting antibody tozorakimab for chronic obstructive pulmonary ...
An AI-powered imaging tool developed by Brainomix has been used to enrich data from a phase 2a trial of Endeavor BioMedicines ...
Speaking to investors and analysts at its capital markets day in London, UK, Sandoz presented its new strategy – Bio100 – ...
At present, the only FDA-approved oral therapies for HAE are BioCryst's Orladeyo (berotralstat) and KalVista Pharma's Ekterly ...
Uniting leaders pioneering complement-targeted therapies across ophthalmology, neurodegeneration, nephrology, oncology and ...
Registration and the full programme are available on the DIA-MHRA Global Summit page. Follow the conversation at ...
Different regions have distinct healthcare systems, varying access levels, reimbursement models, and treatment realities — ...
Hard on the heels of a big disappointment in its cardiovascular pipeline, Novartis has suffered another – this time for its ...
As cell therapy for autoimmune disease transitions from breakthrough clinical case studies to broad clinical validation, developers are racing to overcome challenges around safety, scalability, ...
It's well-established that breathing exercises can improve symptoms in COPD by freeing stale air that remains trapped in the ...
Omnideployment is not about multiplying touchpoints or increasing the volume of communications. It is the precise ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results